| Bioactivity | Caloxin 2A1 is an extracellular plasma membrane Ca2+-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 does not affect basal Mg2+-ATPase or Na+-K+-ATPase[1]. |
| Invitro | Caloxin 2A1 inhibits Ca2+-Mg2+-ATPase in human erythrocyte leaky ghosts, but it does not affect basal Mg2+-ATPase or Na+-K+-ATPase in the ghosts or Ca2+-Mg2+-ATPase in the skeletal muscle sarcoplasmic reticulum. Caloxin 2A1 also inhibits Ca2+-dependent formation of the 140-kDa acid-stable acylphosphate[1].Caloxin 2A1 increases airway smooth muscle cells (ASMCs) apoptosis[2]. |
| Name | Caloxin 2A1 |
| CAS | 350670-85-8 |
| Shortening | VSNSNWPSFPSSGGG-NH2 |
| Formula | C64H91N19O22 |
| Molar Mass | 1478.52 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Caloxin 2A1
CAS: 350670-85-8 F: C64H91N19O22 W: 1478.52
Caloxin 2A1 is an extracellular plasma membrane Ca2+-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 does not affect basal
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.